Medicare Rx Projections: CMS Says Average Per Capita Spending Will Grow 7.5% Per Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Overall prescription drug spending growth will be 10% nationally, but Medicare Part D benefit will be able to keep costs to beneficiaries lower, Medicare trustees report says. CMS estimates size of drug benefit at $85 bil. in first year.
You may also be interested in...
Medicare Trustees Report To Spark Renewed GOP Defense Of Reform Bill
The federal government will start dipping into the Medicare trust fund nine years earlier than expected, moving the insolvency date up to 2019, trustees report. The Medicare reform law’s payments to health plans and rural providers contribute to the revised outlook.
Is The Opioid REMS Too Big To Study?
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Growing Pains For US FDA Oversight Of Opioids: Starting Over On Assessment Of REMS
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: